付强,苗志林,李占全

• 1:辽宁省人民医院心脏中心

摘要(Abstract)：

<正>球囊扩张+药物洗脱支架(DES)已成为经皮冠状动脉介入治疗(PCI)的标准术式。然而,PCI技术仍有很多缺点,人们希望不断有新的器械、技术和策略问世,从而推动冠心病治疗效果不断改善。新近出现的药物洗脱球囊(drugeluting balloon,DEB

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 付强,苗志林,李占全

参考文献(References)：

• [1]Maisel WH.Unanswered questions:drug-eluting stents and the risk of late thrombosis.N Engl J Med,2007,356:981-984.
• [2]Lemos PA,Hoye A,Goedhart D,et al.Clinical,angiographic,and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients:an evaluation from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital(RESEARCH)study.Circulation,2004,109:1366-1370.
• [3]Iofina E,Langenberg R,Blindt R,et al.Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxeleluting stents in the treatment of de novo coronary lesions.Am J Cardiol,2006,98:1022-1027.
• [4]Van der Giessen WJ,Lincoff AM,Schwartz RS,et al.Marked inflammatory sequelaeto implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries.Circulation,1996,94:1690-1697.
• [5]Goldman B,Blanke H,Wolinsky H.Influence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase:a new catheter approach.Atherosclerosis,1987,6:215-225.
• [6]Scheller B,Speck U,Romeike B.Contrast media as carriers for local drug delivery successful inhibition of neointimal proliferation in the porcine coronary stent model.Eur Heart J,2003,24:1462-1467.
• [7]Oberhoff M,Kunert W,Herdeg C,et al.Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porus balloon catheter.Basic Res Cardiol,2001,96:275-282.
• [8]Cremers B,Speck U,Kaufels N,et al.Drug-eluting balloon:very short-term exposure and overlapping.Thromb Haemost,2009,101:201-206.
• [9]Scheller B,Speck R,Abramjuk I,et al.Pacliaxel balloon coating,a novel method for prevention and therapy of restenosis.Circulation,2004,110:810-814.
• [10]Speck U,Scheller B,Abramjuk C.Neointima inhibition:comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries.Radiology,2006,240:411-418.
• [11]Hamm CW.PEPCAD III.Presented at:American Heart Association.Orlando,FL,USA,2009.
• [12]Scheller B,Hehrlein C,Bocksch W.Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.Clin Res Cardiol,2008,97:773-781.
• [13]Unverdorben M,Vallbracht C,Cremers B,et al.Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis.Circulation,2009,119:2986-2994.
• [14]Mathey DG.Pepcad V.Presented at:Transcatheter Cardiovascular Therapeutics.San Francisco,CA,USA,2009.
• [15]Fanggiday JC,Stella PR,Guyomi SH,et al.Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions the DEBIUT(drug-eluting balloon in bifurcaton utrecht)registry Catheter.Cardiovasc Interv,2008,71:629-635.
• [16]Unverdorben M,Kleber FX,Heuer H,et al.Treatment of small coronary arteries with a paclitaxel-coated balloon catheter.Clin Res Cardiol,2010,99:165-174.
• [17]Cortese B,Micheli A,Picchi A,et al.Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels,a prospective randomised clinical trial.Heart,2010,96:1291-1296.